Alpha Teknova, Inc.
TKNO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TKNO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TKNO
Alpha Teknova, Inc. (TKNO) is a life sciences company that manufactures and supplies critical reagents and media for the biopharmaceutical and diagnostics industries, with a focus on supporting research, development, and commercial production.
Key risk: Liquidity and capital adequacy
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Alpha Teknova, Inc. (TKNO) is a life sciences company that manufactures and supplies critical reagents and media for the biopharmaceutical and diagnostics industries, with a focus on supporting research, development, and commercial production.
- Reported total revenue of $12.2M for the six months ended June 30, 2026, with net loss of -$3.2M [sec, as of 2026-06-30].
- Cash and equivalents of $6.0M as of June 30, 2026, with shareholders' equity of $68.8M and total debt of $13.2M [sec, as of 2026-06-30].
- Revenue for Q2 2026 was $12.185M, up from $10.287M in Q2 2025, a 18% increase [sec_mda, as of 2026-08-06].
- Revenue for Q1 2026 was $11.077M, up from $9.795M in Q1 2025 [sec_mda, as of 2026-05-07].
- The company has raised capital through an IPO ($99.1M net), a September 2023 offering ($22.9M gross), and a July 2024 private placement [sec_mda, as of 2024-11-08].
What works
- Revenue has grown year-over-year for each of the last four reported quarters, from $9.614M in Q2 2024 to $12.185M in Q2 2026 [sec_mda, as of 2026-08-06].
- The company has completed the build-out of a new manufacturing facility and made improvements to warehouse and distribution facilities in Hollister, California, indicating investment in capacity [sec_mda, as of 2024-05-13].
- Multiple capital raises (IPO, September 2023 offering, July 2024 private placement) have provided liquidity to fund operations and expansion [sec_mda, as of 2024-11-08].
What to weigh
- The company reported a net loss of -$3.2M for the six months ended June 30, 2026, indicating ongoing unprofitability [sec, as of 2026-06-30].
- Cash and equivalents of $6.0M as of June 30, 2026, are relatively low, and the company has stated that available capital may not be sufficient to meet obligations over the next twelve months if operating results do not improve [sec_mda, as of 2026-03-02].
- The company has an accumulated deficit and has noted that future capital needs are uncertain, requiring additional financing that may not be available on favorable terms [sec_mda, as of 2026-03-02].
From the filings
Quoted directly from source documents.
Risk of insufficient capital over next twelve months
“Our available capital resources may not be sufficient for us to continue to meet our obligations as they become due over the next twelve months if we cannot improve our operating results or increase our operating cash inflows.”
SEC MD&A · March 2, 2026
Risks & what to watch (3)›
Key risks
- Liquidity and capital adequacy — Cash of $6.0M may not be sufficient to meet obligations over the next twelve months if operating results do not improve [sec_mda, as of 2026-03-02].
- Continued net losses — The company reported a net loss of -$3.2M for the six months ended June 30, 2026, indicating ongoing unprofitability [sec, as of 2026-06-30].
- Dependence on additional financing — Future capital needs are uncertain and the company may need to seek additional financing, which may not be available on favorable terms [sec_mda, as of 2026-03-02].
What to watch
- Revenue growth trajectory and ability to achieve profitability, as the company has shown year-over-year revenue increases but remains net loss-making [sec_mda, as of 2026-08-06].
- Cash burn rate and any additional capital raises or financing activities, given the $6.0M cash position and stated liquidity concerns [sec_mda, as of 2026-03-02].
- Operational progress from the new manufacturing facility in Hollister, California, which was built out to support growth [sec_mda, as of 2024-05-13].
Sources: SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run Alpha Teknova, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Alpha Teknova, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
133.0 months
D/E 0.53 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
74
Total value held
$15.5M
| Holder | Shares | Value |
|---|---|---|
| royce & associates lp | 1,069,162 | $3.1M |
| vanguard capital management llc | 883,758 | $2.6M |
| blackrock, inc. | 716,774 | $2.1M |
| millennium management llc | 447,138 | $1.3M |
| geode capital management, llc | 307,873 | $890K |
| bank of america corp /de/ | 228,286 | $660K |
| state street corp | 155,089 | $448K |
| squarepoint ops llc | 124,360 | $359K |
| goldman sachs group inc | 118,439 | $342K |
| morgan stanley | 116,990 | $338K |
Showing top 10 of 74 institutional holders of Alpha Teknova, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 12.2%
- Days to cover
- 10.1
- Shares short
- 1,329,990
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TKNO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Alpha Teknova, Inc.?
Alpha Teknova, Inc. (TKNO) is a life sciences company that manufactures and supplies critical reagents and media for the biopharmaceutical and diagnostics industries, with a focus on supporting research, development, and commercial production.
Who is the CEO of Alpha Teknova, Inc.?
Mr. Stephen Gunstream is the chief executive officer of Alpha Teknova, Inc. (TKNO).
Where is Alpha Teknova, Inc. headquartered?
Alpha Teknova, Inc. (TKNO) is headquartered in Hollister, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.